Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report issued on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock.

Aptose Biosciences Stock Down 5.3 %

Shares of Aptose Biosciences stock opened at $0.36 on Wednesday. The firm has a market capitalization of $6.61 million, a P/E ratio of -0.12 and a beta of 1.26. Aptose Biosciences has a 52 week low of $0.33 and a 52 week high of $2.91. The company has a 50 day moving average price of $0.38 and a 200 day moving average price of $0.64.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC purchased a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences as of its most recent filing with the Securities and Exchange Commission. 26.62% of the stock is currently owned by institutional investors and hedge funds.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.